Title : Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Pub. Date : 2013 Jun

PMID : 23533264






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. cabozantinib ret proto-oncogene Homo sapiens
2 We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508). cabozantinib ret proto-oncogene Homo sapiens
3 We report preliminary data for the first three patients treated with the RET inhibitor cabozantinib on a prospective phase II trial for patients with RET fusion-positive NSCLCs (NCT01639508). cabozantinib ret proto-oncogene Homo sapiens